All In Biotech

Free tool

FAERS Monitor: Revtorpyk

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219908 or its brand name (Revtorpyk, Gedatolisib). Reports on generic versions are filed under their own applications.

Reports

20

Serious

18

90% of reports

Hospitalization

9

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hyperglycaemia7
  • anaemia5
  • drug ineffective4
  • escherichia bacteraemia4
  • leukopenia4
  • pyrexia4
  • pulmonary embolism2
  • cellulitis1
  • colitis1
  • embolism1
  • hyperbilirubinaemia1
  • mania1
  • muscular weakness1
  • myocarditis1
  • nausea1

Reports by year received

View as table
YearReports
20175
20192
20201
20214
20224
20233
20241

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,139 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
escherichia bacteraemiaSignal41792.6745.45,474
hyperglycaemiaSignal7202.1111.21,209
embolism1126.618.731
hyperbilirubinaemia1101.515.024
myocarditis191.813.622
leukopeniaSignal484.135.0251
mania163.99.515
colitis127.74.16
anaemiaSignal527.612.9104
pulmonary embolism222.15.922
cellulitis120.93.14
pyrexiaSignal412.25.131
muscular weakness19.31.41
drug ineffectiveSignal43.21.34
nausea11.30.20

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.